Skip to content

Sexual dysfunction in patients with Myopathies

Sexual Dysfunction in patients with Systemic Autoimmune Myopathies

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2d3pb5t
Enrollment
60
Registered
2026-02-03
Start date
2023-05-03
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physiological Sexual Dysfunction

Interventions

This study will be a controlled and randomized clinical trial with two groups, conducted using a double-blind methodology. Patients diagnosed with myositis will be invited to participate in the study.

Sponsors

Faculdade de Medicina da Universidade de São Paulo
Lead Sponsor
Faculdade de Medicina da Universidade de São Paulo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Older than 18 years; women; diagnosis of systemic autoimmune myopathies; presenting sexual dysfunction

Exclusion criteria

Exclusion criteria: Pregnant; history of gynecological neoplasia; pelvic irradiation; gynecological tract infections; sexually transmitted diseases

Design outcomes

Primary

MeasureTime frame
It is expected to observe an improvement in sexual dysfunction, assessed from the Female Sexual Function Index (FSFI) questionnaire in the Portuguese version, set pre and post-intervention (meetings for sexual orientation), finally, we expect an improvement of 25% between assessments

Secondary

MeasureTime frame
Improvement in quality of life (25%), according to the EuroQol-5D questionnaire (EQ-5D) evaluated pre and post-intervention

Countries

Brazil

Contacts

Public ContactLorenza Silvério da Silva

Faculdade de Medicina da Universidade de São Paulo

lorenza.silverio@usp.br+55(11)3061.7492

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Mar 14, 2026